The inaugural season of the Gomezgil Yaspik Data Science Laboratory marks the beginning of a new chapter for for Bowdoin.
If approved, deucrictibant will be the first oral bradykinin B2 receptor antagonist to treat HAE attacksNDA includes positive data from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results